Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients
Abstract Objectives The objectives of the study are to explore tolerability, acceptability and oncological outcomes for patients with high‐risk non‐muscle‐invasive bladder cancer (NMIBC) treated with hyperthermic intravesical chemotherapy (HIVEC) and mitomycin‐C (MMC) at our institution. Patients an...
Main Authors: | Samantha Conroy, Karl Pang, Ibrahim Jubber, Syed A. Hussain, Derek J. Rosario, Marcus G. Cumberbatch, James W. F. Catto, Aidan P. Noon |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-05-01
|
Series: | BJUI Compass |
Subjects: | |
Online Access: | https://doi.org/10.1002/bco2.203 |
Similar Items
-
3-year experience of hyperthermic intravesical chemotherapy use in patients with high risk non-muscular-invasive bladder cancer
by: R.S. Chystiakov, et al.
Published: (2023-06-01) -
Intravesical adriamycin in the management of bladder tumours Enugu experience
by: Aloy E Aghaji, et al.
Published: (1996-01-01) -
Thiolated Mesoporous Silica Nanoparticles as an Immunoadjuvant to Enhance Efficacy of Intravesical Chemotherapy for Bladder Cancer
by: Cheng‐Che Chen, et al.
Published: (2023-03-01) -
Development and investigation of a novel device with gemcitabine for hyperthermic intravesical chemotherapy
by: Li Jing, et al.
Published: (2023-12-01) -
Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)